Genmab | GEN - Net Income


Genmab reported DKK31M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Almirall EUR 19.58M 7M Dec/2025
Amarin USD -1.22M 6.51M Dec/2025
Amgen USD 2.38B 556M Jun/2026
argenx SE USD 472M 106M Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
Bayer EUR 2.76B 6.52B Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Demant DKK 427M 690M Dec/2025
Exelixis USD 210.47M 34.06M Mar/2026
Fresenius Medical Care EUR 118M 209M Mar/2026
Genmab DKK 31M 370M Dec/2025
GlaxoSmithKline GBP 435M 1.3B Jun/2026
GN Store Nord DKK -955M 1.3B Mar/2026
GRIFOLS EUR 154M 81M Jun/2026
Hikma Pharmaceutical USD 164M 45M Dec/2025
Insmed USD -163.56M 164.92M Mar/2026
Lakefront Biotherapeutics EUR 14.49M 767.65M Mar/2026
Lonza CHF 426M 119M Jun/2025
Merck EUR 659M 340M Mar/2026
Novartis USD 3.26B 108M Jun/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 343M 1.27B Jun/2026
UCB EUR 1.08B 608M Dec/2025